SCHEMBL3793305

SCHEMBL3793305

O=C(O)CCc1c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4)cc32)[nH]c2c1C(=O)CCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
AURKA O14965 20/20 1.00
AURKB Q96GD4 7/20 0.77
PDGFRB P09619 1/20 0.70
FGFR1 P11362 1/20 0.70
KDR P35968 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3793310 1.00 AURKA (1.00) AURKAAURKBPDGFRBFGFR1KDR
SCHEMBL3803661 0.93 AURKA (1.00) AURKAAURKBPDGFRBFGFR1KDR
SCHEMBL3803666 0.93 AURKA (1.00) AURKAAURKBPDGFRBFGFR1KDR
SCHEMBL3792908 0.90 AURKA (1.00) AURKAAURKBPDGFRBFGFR1KDR
SCHEMBL3792901 0.90 AURKA (1.00) AURKAAURKBPDGFRBFGFR1KDR
SCHEMBL3796807 0.90 AURKA (0.82) AURKAAURKBPDGFRBFGFR1KDR
SCHEMBL3796810 0.90 AURKA (0.82) AURKAAURKBPDGFRBFGFR1KDR
SCHEMBL3803707 0.88 AURKA (1.00) AURKAAURKBPDGFRBFGFR1KDR
SCHEMBL3803711 0.88 AURKA (1.00) AURKAAURKBPDGFRBFGFR1KDR
SCHEMBL3800841 0.87 AURKA (1.00) AURKAAURKBPDGFRBFGFR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897602-B2 Indolinone compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2011-03-01 US claimed
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2010-07-15 US claimed
US-7897602-B2 Indolinone compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2011-03-01 US disclosed
US-7897602-B2 Indolinone compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2011-03-01 US disclosed
US-7897602-B2 Indolinone compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2011-03-01 US disclosed
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2010-07-15 US disclosed
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2010-07-15 US disclosed
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors CDK2, MAP3K19, MAP3K20 AURKA 96/4885AURKB 69/4885PDGFRB 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.